Every May, Neurofibromatosis (NF) Awareness Month shines a light on a group of rare genetic conditions that affect thousands of individuals and families yet remain widely misunderstood. These include neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis – distinct disorders with overlapping features but different clinical courses. NF1 is the most common form, accounting for the majority of cases. While many people have never heard of neurofibromatosis, for those living with it, it is a lifelong, complex condition that can impact nearly every aspect of daily life. Understanding NF1: A Complex and Variable Rare Disease NF1 is a genetic condition caused by mutations in the NF1 gene, leading to dysregulation of cell growth and the development of tumours along nerves. It affects approximately 1 in 3,000 individuals globally. Although classified as a rare disease, NF1 affects roughly the same number of people worldwide as multiple sclerosis yet remains far less visible and understood. Its presentation can vary significantly from person to person, ranging from relatively mild symptoms to severe complications. This variability makes diagnosis, monitoring, and treatment particularly challenging, underscoring the need for individualised care. People living with NF1 may experience: -Plexiform neurofibromas (complex nerve tumours that can grow extensively) -Skin manifestations such as café-au-lait spots -Learning and cognitive challenges -Bone abnormalities -Increased risk of certain malignancies And beyond clinical definitions, NF1 can affect education, employment, mental health, and long-term quality of life for both people living with the condition and caregivers. A Shifting Treatment Landscape in NF1 For decades, treatment for NF1 was largely limited to observation and surgical intervention when tumours caused significant complications. However, recent advances in understanding the molecular biology of NF1 have led to meaningful therapeutic progress. NF1 treatment has shifted with the approval of MEK inhibitors. Koselugo (selumetinib) was the first approved therapy for patients with symptomatic, inoperable plexiform neurofibromas, followed by Gomekli / Ezmekly (mirdametinib), further establishing this class as the standard targeted approach. Beyond currently approved therapies, the NF1 pipeline is active and evolving, focusing on improving durability and expanding options through next-generation MEK inhibitors, combination strategies, and novel pathway-targeting agents. Together, these advances signal a maturing therapeutic era in NF1, one that raises new questions around sequencing, long-term benefit, access, and real-world outcomes. Giving a Voice to NF1: Shaping a More Informed and Compassionate Future As the NF1 treatment landscape becomes more complex, market research is playing an increasingly important role in shaping how therapies are developed, positioned, and delivered. In a rare disease like NF1, where patient populations are small and experiences are highly variable, deep insights are critical to: -Illuminate patient and caregiver journeys, identifying unmet needs and treatment pain points -Capture healthcare provider perspectives, particularly in multidisciplinary care settings -Inform clinical trial design, ensuring endpoints and outcomes reflect what matters most to patients -Guide communication strategies, improving awareness and understanding of the condition and new therapies -Support access and adoption, especially as more treatment options become available By bridging the gap between clinical innovation and real-world experience, it’s important to ensure that advances in NF1 translate into meaningful improvements in patient care. At HRW, our Rare Disease team, a group with deep expertise in rare disease market research, dedicated to bringing clarity to complex conditions – has been keeping a pulse on the evolution of this space and the changing treatment paradigm. If you’d like to hear more about NF1 and the evolving treatment landscape, fill in the Contact form below, or email hrw_raredisease@hrwhealthcare.com Apply Now!